Al-Jahdali, Hamdan
Wali, Siraj
Albanna, Amr S.
Allehebi, Riyad
Al-Matar, Hussein
Fattouh, Mohamed
Beekman, Maarten
Funding for this research was provided by:
AstraZeneca, Saudi Arabia (NA, NA, NA, NA, NA, NA, NA)
Article History
Received: 24 March 2021
Accepted: 28 January 2022
First Online: 17 February 2022
Declarations
:
: The protocol was approved by each site’s institutional review board (IRB), and all patients or their guardian provided written informed consent. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, the International Conference on Harmonization guidelines for Good Clinical Practice, the Good Participatory Practice Guidelines, and applicable laws and regulations in each participating country regarding non-interventional studies and/or observational studies. The study was registered at ExternalRef removed (NCT03931954), April 30, 2019. Ethical approvals were granted from: King Abdullah International Medical Research Center, King Abdulaziz University, and King Fahad Medical City.
: Not applicable.
: Mohmed Fattouh is an employee of AstraZeneca GCC and Maarten Beekman is an employee of AstraZeneca International. Hamdan Al-Jahdali, Siraj Wali, Amr S Albanna, Riyad Allehebi, and Hussein Al-Matar have no conflicts of interest to declare.